Written question asked by Rachael Maskell (Labour) on Monday, 10 February 2025, in the House of Commons. It was due for an answer on Wednesday, 12 February 2025. It was answered by Karin Smyth (Labour) on Friday, 14 February 2025 on behalf of the Department of Health and Social Care.
Xanomeline/Trospium Chloride
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the effectiveness of Cobenfy; and whether he is taking steps to licence this medication in the UK.
- Answer
-
The Medicines and Healthcare products Regulatory Agency has not received an application for the Market Authorisation of Cobenfy by the Bristol-Myers Squibb Company.
Secondary information
- Type
- Written question
- Reference
- 30123
- Session
- 2024-26
- Subjects
- Licensing Drugs Schizophrenia Xanomeline/trospium chloride
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-05 20:41:29 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30123
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30123
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30123